Clinical trial of a humanized anti-IL-2/IL-15 receptor β chain in HAM/TSP.

Yoshimi Enose-AkahataUnsong OhJoan OhayonBridgette Jeanne BilliouxRaya MassoudBonita R BryantAshley VellucciNyater NgouthIrene CorteseThomas A WaldmannSteven Jacobson

Published in: Annals of clinical and translational neurology (2019)

The treatment with Hu-Mikβ1 had a number of immunological effects on HAM/TSP patients although no clinical efficacy was observed. We also did not see any dose-related toxicity.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
oxidative stress
randomized controlled trial
phase ii
binding protein
placebo controlled